 The shares of TFFP have slumped, most likely as a result of disappointment over an absence of a deal with one of the top mRNA vaccine producers. However, besides a host of programs developed alone or with partners, the TFF platform remains very relevant for both vaccines as well as therapeutics combating Covid. 